Primary tracheal microcystic reticular schwannoma – Case report of a rare neurogenic tumor treated by segmental tracheal resection

Matthias Esch *, Martin Teschner
Klinik für Thoraxchirurgie, Stadtkrankenhaus Delmenhorst, Wildeshauser Str. 92, D-27753 Delmenhorst, Germany

ARTICLE INFO
Article history:
Received 26 December 2020
Received in revised form 6 January 2021
Accepted 9 January 2021
Available online 16 January 2021

Keywords:
Microcystic reticular schwannoma
Primary tracheal schwannoma
Neurogenic tracheal tumor
Tracheal resection
Rare diseases
Case report

ABSTRACT
INTRODUCTION AND IMPORTANCE: Diagnosis and treatment of rare diseases are challenging because experience and evidence are limited. Primary tracheal tumors have a low prevalence but awareness of these is important to avoid misdiagnoses. We present a first case of a tracheal microcystic reticular schwannoma in which diagnosis and treatment recommendations were revised several times resulting in months of anxious uncertainty for the patient before complete resection and extensive histopathologic examination were performed.

CASE PRESENTATION: A 65-year-old woman complained about coughing and cervical pain. Tomographies revealed a tumor of the dorsolateral trachea. After repeated biopsies pathologists and tumorboards in different hospitals could not agree on diagnosis or treatment recommendation, so the impatient patient opted for a complete resection for definitive treatment.

CLINICAL DISCUSSION: Neoplasms of the posterior mediastinum are mainly neurogenic. In rare cases they may originate in the trachea and can be difficult to differentiate from other tumor entities if only biopsies are available. Although the preoperative diagnosis was unclear, tracheal resection was performed successfully. The differential diagnoses of soft tissue sarcoma or myoepithelioma were discarded and a benign, microcystic, reticular schwannoma was confirmed by international reference pathologists.

CONCLUSION: Microcystic, reticular schwannoma is a rare variant and may occur in the trachea. Diagnosis of such rare neoplasms can be difficult, resulting in delayed or suboptimal treatment. Often biopsies are not sufficient to reach a definite diagnosis. But even without preoperative histology, tracheal resection is a safe and feasible option for definitive treatment with very low recurrence rates.

© 2021 The Author(s). Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Pathology may be easy at times, but in some cases, it can be difficult to reach a diagnosis, especially when rare tumors are concerned. Due to low incidences, experience with these entities is limited or diagnostic criteria may not be well defined. In addition, these neoplasms can show overlapping features with other diseases.

This case report, prepared in line with the updated SCARE-criteria [1], presents a first case of a rare variant of a neurogenic, primary tracheal tumor, where the patient experienced a long course of different diagnostic procedures and was unsettled by contradicting treatment recommendations.

2. Patient information

A woman of 65 years, non-smoker, with hypertension and a uterine carcinoma treated by hysterectomy 20 years before, had consulted her orthopedist because of cervical pain, slowly progressing over a period of 7 months. Her family history included adenocarcinoma of mamma and colon. Antihypertensive medication and non-steroidal anti-inflammatory drugs had been prescribed. She had been working in a company office for 35 years and retired one year before.

3. Clinical findings

In the weeks before the consultation she complained about coughing, hoarseness under physical strain and intermittent dysphagia. At this point neurological symptoms were absent, but shortly later she developed paresthesia and weakness of her right arm. There was neither weight loss, nor fatigue or other limitation.

https://doi.org/10.1016/j.ijscr.2021.01.016
2210-2612/© 2021 The Author(s). Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
The resected material was sent to two different, specialized, international histopathological institutes, who described a primary tracheal tumor with slightly eosinophilic, spindle-shaped or ovoid cells arranged around either myxoid matrix or microcystic spaces. Absence of atypia or pleomorphism was confirmed. A diffuse positivity for S100 and focal positivity for CD34 was seen. Staining for epithelial membrane antigen (EMA) showed an incomplete perineural capsule. The reference pathologists agreed on the diagnosis of a benign, microcystic/reticular schwannoma (MRS) (Figs. 3 and 4).

6. Follow up and outcome

The patient recovered well, the follow up over 8 years showed no recurrence or tracheal stenosis. She showed no dyspnea under moderate physical exercise, but a slight dysphonia, caused by unilateral, partial laryngeal paralysis.

7. Discussion

Benign Schwannoma of the head, neck, peripheral nerves or the gastrointestinal tract are well known. Sporadically arising from intercostal or sympathetic nerves they also account for 95% of posterior mediastinal neoplasms [2]. In contrast, the incidence of primary tracheal malignancies is low, but epidemiological data can be derived from national registries. The Netherlands Cancer Registry showed an annual incidence of only 0.142/100.000 [3], the NCI Surveillance, Epidemiology and End Results Register (SEER) reported 0.26/100.000 [4]. In adults 90% of primary tracheal tumors are malignant, therefore the incidence of benign tracheal neoplasms is much lower and no epidemiological data are available for these lesions. The WHO-classification of tumors lists tracheal tumors together with head-/neck tumors rather than tumors of the bronchi, reflecting the position of the trachea as an “interface” where neoplasms of different regions may overlap, making a correct diagnosis quite challenging [5]. This applies even more, when only limited material is available for histopathologic examination, as it was in the presented case.

A few cases of primary tracheal schwannoma have been reported and these publications describe classical schwannoma showing specific features like alternating Antoni A and B regions, hyalinized vessels, Verocay bodies, a capsule and positivity for S-100 and EMA. Only in one case a melanotic psammomatosi variant was identified. The incidence of these primary schwannomas is higher in the lungs or the peripheral bronchopulmonary tree, but decreases with central location. Clinical symptoms are usually caused by obstruction of the upper airways. They include dyspnoea, coughing or hemoptysis. Even with these classical schwannoma a substantial delay of 10–17 months was seen until definite diagnosis [6].

A variety of schwannoma subforms with distinct histologies and different predilections have been defined in which the typical features of classical schwannoma may not or only partly be present and which may show overlapping features with non-neurogenic neoplasms like sarcoma, gastrointestinal stroma or salivary gland tumors [7]. In 2008 Liegl et al. described a new schwannoma variant with a predilection for the gastrointestinal tract but sporadic occurrences in other organs. This subform lacks the typical features of classical schwannoma but shows a predominant or exclusive reticular pattern of intersecting spindle cell strands with eosinophilic plasma creating microcystic spaces of myxoid material or fibrillary collagen. Atypia is absent, but the mostly uncapsulated boundary may show a pushing growth pattern invading between neighbouring cells in a pseudoinfiltrating way. A strong immunohistochemical S-100-positivity, negative cytokeratins, a
variable positivity for glial fibrillary acidic protein (GFAP) and minor areas with classical features or remnants of an EMA-positive perineural capsule led to the classification as a benign microcystic/reticular variant of schwannoma [8].

In a review Liu et al. [9] collected 36 cases of MRS. These included 14 (39%) in the gastrointestinal tract, 8 (22%) in the subcutaneous or soft tissue, 7 (19%) in the head/neck region, 5 (14%) in endocrine glands (pancreatic, adrenal), 1 (3%) in the lumbar spinal canal and a single bronchial case published in the original case series [8]. Therefore, to our knowledge this is the first report of a tracheal MRS.

Tracheal obstruction is an incriminating condition, requiring short term desobliterating therapy. Pedunculated or small tracheal tumors may be treated by a variety of endoscopic methods with good results, but sessile tumors with intra- or transmural growth showed recurrence rates as high as 21% after endoscopic resection whereas it was 0% for surgically resected schwannoma [6,10,11]. Radiotherapy plays a role in the adjuvant treatment of tracheal malignancies, but not in the management of benign tracheal diseases [12,13]. In these cases, tracheal resection is the treatment of choice.

In the Netherlands only 12% of malignant tracheal tumors were resected, although more than 50% of the patients were candidates for surgical treatment [14]. The same findings of surgically undertreated tracheal malignancies were reported in other cohorts [4,15]. There is a strong probability, that the same applies for benign tracheal neoplasms, as illustrated in this reported case, where the first treatment recommendations did not include surgery.

**Fig. 2.** F18-FDG-PET/CT with a singular tracheal tumor with enhanced glucose metabolism (SUV max 6.6) and MRI showing a paravertebral mass in T2-pictures with homogenous hyperintensity and no capsular enhancement, T1 showed a low intensity (yellow arrow).

**Fig. 3.** Histopathology showing normal tracheal mucosa and underneath it a mass of loosely scattered blastoid cells (left) with eosinophilic plasma, spindle-shaped or ovoid nuclei, interspaced myxoid material in microcystic spaces (middle) and occasional bud-like protrusions and infiltrations into the mucosa (right).

**Fig. 4.** Tracheal anastomosis after segmental resection intraoperative (left), after 1 week (middle) and after 2 weeks (right).
About 50% of the trachea can be resected in adults with good neck flexibility via a collar incision with optional manubriotomy or sternotomy. In elderly patients with kyphosis the length of possible resection may be considerably less. Long term results are excellent, although when carinal resections are included, operative mortality may be as high as 10% in patients with tracheal carcinoma depending on the length of resected trachea, tissue infiltration or preoperative high dose irradiation [12,13,16,17].

In summary, schwannoma variants like MRS lacking the features of classical schwannoma may occur in the trachea and make a correct diagnosis extremely challenging. As a result, delay of diagnosis is frequent, incorrect diagnosis and suboptimal treatment recommendations are common. Upper airway obstruction demands short term desobliterring treatment, so repeated diagnostic interventions causing unnecessary delays are not indicated. Although it seems to be undervalued, tracheal resection offers definitive treatment and sufficient material for a histopathological diagnosis with good results and low recurrence rates.

8. Patient perspective

When contacted for written consent, the patient expressed her satisfaction with the decision for a resection to end months of anxious discomfort and uncertainty. Although logopedic training had not improved her dysphonia, she did not experience relevant impairment in everyday life.

Declaration of Competing Interest

The authors have no conflicts of interest.

Funding

This publication did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Ethical approval

This clinical case report is exempt from the need of ethical approval in our institution.

Consent

Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request.

Author contribution

ME: The corresponding author contributed the collection of case details and images, literature work, obtaining of patient consent, writing of the paper.

MT: advise, revision and final approval.

Registration of research studies

Not Applicable.

Guarantor

The corresponding author accepts full responsibility for the work and the decision to publish.

Provenance and peer review

Not commissioned, externally peer reviewed.

References

[1] R.A. Agha, T. Franchi, C. Sohrabi, G. Mathew, A. Kerwan, A. Thoma, A.J. Beamish, A. Nouelldin, A. Rao, B. Vasudevan, B. Challacombe, B. Perakath, B. Kirshtein, R. Ekser, C.S. Pramesh, D.M. Laskin, D. Machado-Aranda, D. Miguel, D. Pagano, F.H. Millham, G. Roy, H. Kadioglu, J.J. Nixon, I. Mukhejee, J.A. McCaul, J. Chi-Yong Ngui, J. Albrecht, J.G. Rivas, K. Raveendran, L. Derbyshire, M.H. Ather, M.A. Thorat, M. Valmasoni, M. Bashashati, M. Chalko, N.Z. Teo, N. Raisa, O.I. Muensterer, P.J. Bradley, P. Goel, P.S. Pai, R.Y. Affif, R.D. Rosin, R. Coppola, R. Klappenberg, R. Wynn, R.I. De Wilde, S. Surani, S. Giordano, S. Massarut, S.G. Raja, S. Basu, S.A. Enam, T.G. Manning, T. Cross, V.K. Karkanth, V. Kasivisvanathan, Z. Mei, The SCARE 2020 guideline: updating consensus Surgical Case Report (SCARE) guidelines, Int. J. Surg. (2020) 1–5, http://dx.doi.org/10.1016/j.ijsu.2020.10.034.

[2] G. Cardillo, F. Carleo, M.W. Khalil, L. Carbone, S. Treggiari, L. Salvadori, L. Petrella, M. Martelli, Surgical treatment of benign neurogenic tumours of the mediastinum: a single institution report, Eur. J. Cardiothorac. Surg. 34 (2008) 1210–1214, http://dx.doi.org/10.1016/j.ejcts.2008.09.006.

[3] J. Honings, J.A.A.M. van Dijck, A.F.T.M. Verhagen, H.F.M. van der Heijden, H.A.M. Marres, Incidence and treatment of tracheal cancer: a nationwide study in the Netherlands, Ann. Surg. Oncol. 14 (2007) 968–976, http://dx.doi.org/10.1245/s10434-006-9229-z.

[4] A.L. Urdaneta, J.B. Yu, L.D. Wilson, Population based cancer registry analysis of primary tracheal carcinoma, Am. J. Clin. Oncol. 34 (2011) 32–37, http://dx.doi.org/10.1097/COC.0b013e318ce8a8b.

[5] K. Junker, Pathology of tracheal tumors, Thorac. Surg. Clin. 24 (2014) 7–11, http://dx.doi.org/10.1016/j.thorsci.2013.09.006.

[6] S. Hamouri, N.M. Novotny, Primary tracheal schwannoma: a review of a rare entity: current understanding of management and followup, J. Cardiothorac. Surg. 12 (2017) 105, http://dx.doi.org/10.1186/s11613-017-0677-2.

[7] F.J. Rodriguez, A.L. Folpe, C. Giannini, A. Perry, Pathology of peripheral nerve sheath tumors: diagnostic overview and update on selected diagnostic problems, Acta Neuropathol. 123 (2012) 295–319, http://dx.doi.org/10.1007/s00401-012-0954-z.

[8] M.J. Liegl, M.W. Bennett, C.D.M. Fletcher, Microcystic/reticular schwannoma: a distinct variant with predilection for visceral locations, Ann. J. Surg. Pathol. 32 (2008) 1080–1087, http://dx.doi.org/10.1097/01.PAS.0000318160.c0fda.

[9] C. Liu, L. Yan, Q. Liu, J. Li, H. Jin, J. Wang, Y. Deng, Lumbar intraspinal microcystic/reticular schwannoma case report and literature review, Medicine (Baltimore) 97 (2018), e12474, http://dx.doi.org/10.1097/MD.0000000000012474.

[10] X. Ge, F. Han, W. Guan, J. Sun, X. Guo, Optimal treatment for primary benign intratracheal schwannoma: a case report and review of the literature, Oncol. Lett. 10 (2015) 2273–2276, http://dx.doi.org/10.3892/ol.2015.3521.

[11] K. Kasahara, K. Fukuoka, M. Konishi, K. Hamada, K. Maeda, K. Mikasa, H. Kimura, Two cases of endobronchial neuromiroma and review of the literature in Japan, Intern. Med. 42 (2003) 1215–1218, http://dx.doi.org/10.1007/s11606-005-07054-6.

[12] P. Macchiari, Primary tracheal tumours, Lancet Oncol. 7 (2006) 83–91, http://dx.doi.org/10.1016/s1470-2045(05)70541-6.

[13] M. L. Madariaga, H.A. Gaisert, Overview of malignant tracheal tumours, Ann. Cardiothorac. Surg. 7 (2018) 244–254, http://dx.doi.org/10.21037/acs.2018.03.04.

[14] J. Honings, H.A. Gaisert, A.F.T.M. Verhagen, J.A.A.M. van Dijck, H.F.M. van der Heijden, L. Die, J. Bussink, J.H.A.M. Kaanders, H.A.M. Marres, Undertreatment of tracheal carcinoma: multidisciplinary audit of epidemiologic data, Ann. Surg. Oncol. 16 (2009) 246–253, http://dx.doi.org/10.1245/s10434-008-0241-3.

[15] P.B. Licht, S. Fries, G. Pettersson, Tracheal cancer in Denmark: a nationwide study, Eur. J. Cardiothorac. Surg. 19 (2001) 339–345, http://dx.doi.org/10.1016/s0145-4298(01)00597-8.

[16] H.A. Gaisert, H.C. Grillo, M.B. Shadmeher, C.D. Wright, M. Gokhale, J.C. Wain, D.J. Mathiesen, Uncommon primary tracheal tumours, Ann. Thorac. Surg. 82 (2006) 268–273, http://dx.doi.org/10.1016/j.athoracsur.2006.01.055.

[17] J.F. Regnard, P. Fourquier, P. Levassuer, Results and prognostic factors in resections of primary tracheal tumours: a multicenter retrospective study. The French Society of Cardiovascular Surgery, J. Thorac. Cardiovasc. Surg. 111 (1996) 804–808.